# US 2024/0189397 A1 · Heparin-Associated Polypeptides and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189397 A1
- Document ID: US20240189397A1
- Status: Published application
- Kind: A1
- Application number: 17/843,676
- Filed: 2020-12-22
- Published: 2024-06-13
- Earliest claimed: 2019-12-24
- Assignees: Juvena Therapeutics, Inc.
- Applicants: Juvena Therapeutics, Inc.
- Inventors: Hanadie Yousef; Jeremy O'Connell; Thach Mai; Rami Jaafar
- Web page: https://patentgrep.com/patent/US20240189397A1

## CPC

- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 38/1709: {from mammals}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method for treating muscle, comprising the steps of:
obtaining a subject suffering from a muscle-wasting condition; and
treating the subject with a composition wherein the composition comprises a polypeptide of Table 2, and wherein the administration increases expression of MYOG, MYOD1, MYH3, CK, or ATP1B1.

### Claim 26 (depends on 25)

The method of claim 25, wherein the polypeptide of Table 2 comprises an IGF2 polypeptide, a FGF17 polypeptide, a BMP7 polypeptide, a TGFb1 polypeptide, a FGF1 polypeptide, or a PDGFD polypeptide.

### Claim 27 (depends on 26)

The method of claim 26, wherein the treating the subject increases a regenerative capability of a myoblast of the subject, the regenerative capability comprising a proliferation, a degree of differentiation, or a cellular survival.

### Claim 28 (depends on 27)

The method of claim 27, wherein the increase in the regenerative capability of the myoblast comprises an increase in proliferation of the myoblast, resulting in an increase in new myofibers.

### Claim 29 (depends on 27)

The method of claim 27, wherein the subject has an increase in a muscle regeneration.

### Claim 30 (depends on 25)

The method of claim 25, wherein a grip strength of the subject is increased.

### Claim 31 (depends on 25)

The method of claim 25, wherein a weight of muscle in the subject is increased.

### Claim 32 (depends on 25)

The method of claim 25, wherein a forelimb force in the subject is increased.

### Claim 33 (depends on 25)

The method of claim 25, wherein a lean body mass of the subject is increased.

### Claim 34 (depends on 25)

The method of claim 25, wherein an appendicular skeletal muscle index of the subject is increased.

### Claim 35 (depends on 25)

The method of claim 25, wherein the muscle-wasting condition is a sarcopenia.

### Claim 36 (depends on 25)

The method of claim 25, wherein the muscle-wasting condition is a muscular dystrophy.

### Claim 37 (depends on 25)

The method of claim 25, wherein the muscle-wasting condition is a result of an obesity, a disease progression, a metabolic disorder, a therapeutic treatment, or a combination thereof.

### Claim 38 (depends on 25)

The method of claim 25, wherein the muscle-wasting condition is a cachexia.

### Claim 39 (depends on 37)

The method of claim 37, wherein the metabolic disorder is a diabetes.

### Claim 40 (depends on 25)

The method of claim 25, wherein the muscle-wasting condition results from a muscle injury, or a limb immobilization.

### Claim 41 (depends on 26)

The method of claim 26, wherein the polypeptide has a modification to improve stability.

### Claim 42 (depends on 41)

The method of claim 41, wherein the modification is a chemical medication.

### Claim 43 (depends on 41)

The method of claim 41, wherein the modification is a conjugation to another protein.

### Claim 44 (depends on 43)

The method of claim 43, wherein the other protein is a serum albumin or an immunoglobulin.
